DE69934885D1 - Neue methoden und interferon defiziente substrate zur vermehrung von viren - Google Patents

Neue methoden und interferon defiziente substrate zur vermehrung von viren

Info

Publication number: DE69934885D1
Authority: DE; Germany
Prior art keywords: viruses; attenuated; ifn; relates; improvement
Prior art date: 1998-06-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69934885T

Other languages

English (en)

Other versions

DE69934885T2 (de

Inventor

Peter Palese

Adolfo Garcia-Sastre

Robert O'neil

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Icahn School of Medicine at Mount Sinai

Original Assignee

Mount Sinai School of Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

1999-06-11

Publication date

2007-03-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27376229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69934885(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-11 Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine

2007-03-08 Publication of DE69934885D1 publication Critical patent/DE69934885D1/de

2007-11-08 Application granted granted Critical

2007-11-08 Publication of DE69934885T2 publication Critical patent/DE69934885T2/de

2019-06-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16241—Use of virus, viral particle or viral elements as a vector
- C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16261—Methods of inactivation or attenuation
- C12N2760/16262—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE69934885T 1998-06-12 1999-06-11 Neue methoden und interferon defiziente substrate zur vermehrung von viren Expired - Lifetime DE69934885T2 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US8910398P	1998-06-12	1998-06-12
US89103P		1998-06-12
US10883298P	1998-11-18	1998-11-18
US108832P		1998-11-18
US11768399P	1999-01-29	1999-01-29
US117683P		1999-01-29
PCT/US1999/013142 WO1999064570A1 (en)	1998-06-12	1999-06-11	Novel methods and interferon deficient substrates for the propagation of viruses

Publications (2)

Publication Number	Publication Date
DE69934885D1 true DE69934885D1 (de)	2007-03-08
DE69934885T2 DE69934885T2 (de)	2007-11-08

Family

ID=27376229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69934885T Expired - Lifetime DE69934885T2 (de)	1998-06-12	1999-06-11	Neue methoden und interferon defiziente substrate zur vermehrung von viren

Country Status (24)

Country	Link
US (12)	US6573079B1 (de)
EP (4)	EP2316924B1 (de)
JP (7)	JP4837827B2 (de)
KR (2)	KR100637937B1 (de)
CN (1)	CN1312725A (de)
AT (1)	ATE351901T1 (de)
AU (2)	AU771110B2 (de)
BR (1)	BR9911163A (de)
CA (2)	CA2334895C (de)
CY (1)	CY1113689T1 (de)
CZ (2)	CZ306637B6 (de)
DE (1)	DE69934885T2 (de)
DK (4)	DK2316923T3 (de)
ES (4)	ES2400445T3 (de)
HU (1)	HUP0102441A3 (de)
IL (6)	IL140264A0 (de)
MX (2)	MXPA00012403A (de)
NO (1)	NO20006328L (de)
NZ (2)	NZ509054A (de)
PL (3)	PL219128B1 (de)
PT (1)	PT1085904E (de)
RU (1)	RU2236252C2 (de)
SK (3)	SK288567B6 (de)
WO (2)	WO1999064068A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7470426B1 (en)	1997-10-09	2008-12-30	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
WO2000062735A2 (en) *	1999-04-15	2000-10-26	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US7780962B2 (en)	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
RU2236252C2 (ru) *	1998-06-12	2004-09-20	Маунт Синай Скул Оф Медсин Оф Дзе Сити Юниверсити Оф Нью-Йорк	Аттенуированные вирусы с минус-цепью с измененной антагонистической в отношении интерферона активностью для применения в качестве вакцин и фармацевтических веществ
ES2320239T3 (es)	1999-09-17	2009-05-20	Wellstat Biologics Corporation	Virus oncolitico.
US8147822B1 (en)	1999-09-17	2012-04-03	Wellstat Biologics Corporation	Oncolytic virus
US6800288B2 (en)	2000-03-02	2004-10-05	Polymun Scientific Immunbiologische Forschung Gmbh	Recombinant influenza A viruses
AU2001257001A1 (en) *	2000-04-10	2001-10-23	Mount Sinai School Of Medicine Of New York University	Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) *	2000-04-26	2001-10-31	Conzelmann Karl Klaus	RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
AU2356002A (en) *	2000-09-25	2002-04-02	Polymun Scient Immunbio Forsch	Live vaccine and method of manufacture
MX352687B (es)	2001-02-14	2017-12-04	Anthrogenesis Corp	Placenta de mamiferos postparto, su uso y celulas madres placentales extraidas de ella.
WO2002094423A1 (en)	2001-05-22	2002-11-28	Access Business Group International Llc	Method and apparatus for blending and dispensing liquid compositions
CN1549709A (zh)	2001-07-16	2004-11-24	��ɯ�ס��ڵ��ɿ�	一类抗病毒化合物在制造用于治疗或预防在呼吸道中病毒感染的制剂中的应用
US7037707B2 (en) *	2003-09-04	2006-05-02	St. Jude Children's Research Hospital	Method for generating influenza viruses and vaccines
CN1993140A (zh)	2004-06-01	2007-07-04	纽约大学西奈山医学院	遗传工程猪流感病毒及其应用
WO2006088481A2 (en) *	2005-02-15	2006-08-24	Mount Sinai School Of Medicine Of New York University	Genetically engineered equine influenza virus and uses thereof
AT502275B8 (de) *	2005-08-08	2007-08-15	Greenhills Biotechnology Res D	Immunantwort-induzierende zusammensetzungen
KR101492643B1 (ko)	2005-12-02	2015-02-12	이칸 스쿨 오브 메디슨 엣 마운트 시나이	비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
EP1911836A1 (de)	2006-10-12	2008-04-16	AVIR Green Hills Biotechnology Trading GmbH	Mediumzusatz für die Virusproduktion
US7860646B2 (en) *	2007-04-16	2010-12-28	The Boeing Company	Method and apparatus for routing ocean going vessels to avoid treacherous environments
WO2008144067A1 (en) *	2007-05-21	2008-11-27	Board Of Regents, University Of Texas System	Methods and compositions for treatment of cancer using oncolytic rsv activity
EP2048237A1 (de)	2007-10-05	2009-04-15	Avir Green Hills Biotechnology Research Development Trade Ag	Replikationsdefizienter Influenza-Virus zur Expression heterologer Sequenzen
EP2045323A1 (de) *	2007-10-05	2009-04-08	Avir Green Hills Biotechnology Research Development Trade Ag	Linearische Expressionskonstrukte zur Herstellung von Partikeln des Influenzavirus
EP2072058A1 (de)	2007-12-21	2009-06-24	Avir Green Hills Biotechnology Research Development Trade Ag	Modifiziertes Influenzavirus
US8108138B2 (en) *	2008-10-02	2012-01-31	The Boeing Company	Optimal vehicle router with energy management system
EP2364167B1 (de)	2008-11-25	2016-08-17	Nanotherapeutics, Inc.	Verfahren zur herstellung eines ph-stabilen ummantelten virus
EP2233568A1 (de)	2009-03-19	2010-09-29	Avir Green Hills Biotechnology Research Development Trade AG	Neues Verfahren zur Herstellung eines RNA Virus
CN102257135B (zh) *	2008-12-16	2017-06-09	纳米医疗公司	流感疫苗的生产
EP2233152A1 (de)	2009-03-24	2010-09-29	Avir Green Hills Biotechnology Research Development Trade Ag	Schnell wachsender reassortanter Influenza-A-Virus
US8935174B2 (en) *	2009-01-16	2015-01-13	The Boeing Company	Analyzing voyage efficiencies
US8591881B2 (en)	2009-02-05	2013-11-26	Mount Sinai School Of Medicine	Chimeric Newcastle disease viruses and uses thereof
CA2787099A1 (en)	2009-03-30	2010-10-14	Anice C. Lowen	Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CA2763816A1 (en)	2009-04-27	2010-11-04	Novartis Ag	Adjuvanted vaccines for protecting against influenza
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
EP2451940A4 (de) *	2009-07-06	2013-08-28	Alnylam Pharmaceuticals Inc	Bioverarbeitung
WO2011009864A1 (en)	2009-07-22	2011-01-27	Avir Green Hills Biotechnology Research Development Trade Ag	Novel influenza virus
US9217157B2 (en)	2009-07-27	2015-12-22	Icahn School Of Medicine At Mount Sinai	Recombinant influenza viruses and uses thereof
CA2805505C (en)	2009-07-30	2021-08-03	Mount Sinai School Of Medecine	Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
CN104862335A (zh)	2009-07-31	2015-08-26	诺华股份有限公司	反向遗传系统
EP2295543A1 (de) *	2009-09-11	2011-03-16	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Verfahren zur Herstellung von Influenzaviren
MX2012011300A (es)	2010-03-30	2012-11-29	Sinai School Medicine	Vacunas del virus de influenza y usos de las mismas.
US8597637B1 (en)	2010-05-18	2013-12-03	Weidong Zhang	Breast cancer therapy using an engineered respiratory syncytial virus
CA2801268A1 (en) *	2010-06-02	2011-12-08	Avir Green Hills Biotechnology Research Development Trade Ag	Novel method for generation of rna virus
US9044499B1 (en)	2010-06-22	2015-06-02	Weidong Zhang	NS1/2-deficient respiratory syncytial virus and melanoma treatment
US8377901B2 (en) *	2010-07-07	2013-02-19	The University Of Manitoba	Target host factors for treating viral infection
CN102021148A (zh) *	2010-07-27	2011-04-20	张卫东	一种基因ns1缺陷型呼吸道合胞病毒及其应用
CN102021149B (zh) *	2010-07-27	2013-04-24	张卫东	基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用
SG11201400743VA (en)	2011-09-20	2014-04-28	Sinai School Medicine	Influenza virus vaccines and uses thereof
US9157746B2 (en)	2011-11-16	2015-10-13	The Boeing Company	Vessel routing system
US9371366B2 (en)	2012-12-18	2016-06-21	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccines and uses thereof
CN103330723A (zh) *	2013-01-14	2013-10-02	艾克星（武汉）生物医药科技有限公司	基因工程呼吸道合胞病毒（△ns1 rsv)在治疗癌症药物中的用途
US10947543B2 (en)	2013-03-13	2021-03-16	Yale University	Interferon production using short RNA duplexes
NZ711946A (en)	2013-03-14	2020-05-29	Icahn School Med Mount Sinai	Newcastle disease viruses and uses thereof
WO2014159960A1 (en)	2013-03-14	2014-10-02	Icahn School Of Medicine At Mount Sinai	Antibodies against influenza virus hemagglutinin and uses thereof
WO2015127501A1 (en)	2014-02-27	2015-09-03	Viralytics Limited	Combination method for treatment of cancer
WO2016118937A1 (en)	2015-01-23	2016-07-28	Icahn School Of Medicine At Mount Sinai	Influenza virus vaccination regimens
EA201791907A1 (ru)	2015-02-26	2018-02-28	Бёрингер Ингельхайм Ветмедика Гмбх	Бивалентная вакцина против вируса свиного гриппа
US10947512B2 (en)	2015-08-14	2021-03-16	Research Institute At Nationwide Children's Hospital	Respiratory syncytial virus having altered NS1 protein function and related materials and methods
RU2660562C2 (ru) *	2016-03-30	2018-07-06	Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ"	Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
EA037571B1 (ru) *	2015-11-06	2021-04-15	Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ"	Аттенуированный вирус гриппа а, аттенуированный грипозный вектор, фармацевтическая композиция и их применение для профилактики или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
RU2628690C2 (ru) *	2015-11-06	2017-08-21	Общество С Ограниченной Ответственностью 'Фарминтерпрайсез'	Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
US11174466B2 (en)	2015-11-24	2021-11-16	Commonwealth Scientific And Industrial Research Organisation	Production of viruses in cell culture
WO2017088017A1 (en) *	2015-11-24	2017-06-01	Commonwealth Scientific And Industrial Research Organisation	Production of viruses in avian eggs
CN109641041A (zh)	2016-06-15	2019-04-16	西奈山伊坎医学院	流感病毒血细胞凝集素蛋白及其用途
EP3559216A1 (de)	2016-12-22	2019-10-30	Blue Sky Vaccines GmbH	Verfahren zur reinigung eines virus
CN111511907A (zh)	2017-03-14	2020-08-07	加利福尼亚大学董事会	对病毒中免疫逃逸功能区域的全基因组鉴定
CA3058652A1 (en)	2017-04-07	2018-10-11	Icahn School Of Medicine At Mount Sinai	Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
AU2018363202B2 (en)	2017-11-08	2024-10-03	Blue Sky Vaccines Gmbh	SO3 chromatography for use in a method for virus purification
US20220160863A1 (en)	2019-01-24	2022-05-26	Blue Sky Vaccines Gmbh	High growth influenza virus
WO2020163768A1 (en) *	2019-02-07	2020-08-13	Duke University	Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
KR102370100B1 (ko) *	2019-02-15	2022-03-07	아이디바이오 주식회사	이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
BR112021024409A2 (pt) *	2019-06-07	2022-01-18	Intervet Int Bv	Célula mutante nocaute de mdbk irf3/irf7 e seu uso para produção de vacina
JP7222552B2 (ja) *	2020-01-30	2023-02-15	国立研究開発法人農業・食品産業技術総合研究機構	豚デルタコロナウイルスの増殖方法
EP4251200B1 (de) *	2020-11-30	2024-10-30	BlueSky Immunotherapies GmbH	Neues replikationsdefizientes influenza-a-virus zur induktion hoher konzentrationen von interferon vom typ i
US20240035035A1 (en) *	2020-12-09	2024-02-01	Yale University	Compositions and methods for treating, ameliorating, and/or preventing viral infections
WO2022261206A1 (en)	2021-06-09	2022-12-15	Icahn School Of Medicine At Mount Sinai	Gene combination as a broad spectrum antiviral
CN115896035B (zh) *	2022-12-22	2024-04-16	苏州沃美生物有限公司	一种应用于病毒扩增的Vero细胞株、其构建方法及应用
WO2025019631A1 (en)	2023-07-19	2025-01-23	Icahn School Of Medicine At Mount Sinai	Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4071618A (en) *	1974-09-03	1978-01-31	Research Foundation For Microbial Diseases Of Osaka University	Process for preparing virus disease live vaccines
US4215051A (en)	1979-08-29	1980-07-29	Standard Oil Company (Indiana)	Formation, purification and recovery of phthalic anhydride
JPS57136528A (en)	1981-02-09	1982-08-23	Hayashibara Biochem Lab Inc	Preparation of viral vaccine
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
JPS5939831A (ja) *	1982-08-27	1984-03-05	Biseibutsu Kagaku Kenkyusho:Kk	豚用インフルエンザウイルス不活化ワクチン
US5106619A (en)	1983-12-20	1992-04-21	Diamond Scientific Co.	Preparation of inactivated viral vaccines
US4693981A (en)	1983-12-20	1987-09-15	Advanced Genetics Research Institute	Preparation of inactivated viral vaccines
JPS60202827A (ja) *	1984-03-28	1985-10-14	Chibaken	弱毒痘そうワクチン株
US5854037A (en)	1989-08-28	1998-12-29	The Mount Sinai School Of Medicine Of The City University Of New York	Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en)	1989-08-28	1992-11-24	The Mount Sinai School Of Medicine Of The City University Of New York	Recombinant negative strand rna virus expression-systems
US5786199A (en)	1989-08-28	1998-07-28	The Mount Sinai School Of Medicine Of The City University Of New York	Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en)	1989-08-28	1998-11-24	Aviron	Recombinant negative strand RNA virus expression systems
US5766601A (en)	1990-08-08	1998-06-16	University Of Massachusetts Medical Center	Cross-reactive influenza a immunization
DE69223638T2 (de)	1991-10-07	1998-05-20	Biogen, Inc., Cambridge, Mass.	Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
US6162432A (en)	1991-10-07	2000-12-19	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE69311764T2 (de)	1992-05-14	1998-02-05	Polymun Scient Immunbio Forsch	Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
US7344722B1 (en)	1993-06-29	2008-03-18	The Regents Of The University Of Michigan	Cold-adapted influenza virus
DK0702085T4 (da)	1994-07-18	2010-04-06	Conzelmann Karl Klaus Prof Dr	Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US6300090B1 (en)	1994-07-29	2001-10-09	The Rockefeller University	Methods of use of viral vectors to deliver antigen to dendritic cells
US6146873A (en)	1994-11-10	2000-11-14	Baxter Aktiengesellschaft	Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en)	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
EP0780475B2 (de)	1995-08-09	2006-07-19	SCHWEIZ. SERUM- & IMPFINSTITUT BERN	Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US5840565A (en) *	1995-08-22	1998-11-24	The Regents Of The University Of California	Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
WO1997012032A1 (en)	1995-09-27	1997-04-03	The Government Of The United States Of America, As Represented By The Department Of Health And Human Services	Production of infectious respiratory syncytial virus from cloned nucleotide sequences
GB9605808D0 (en) *	1996-03-20	1996-05-22	Isis Innovation	CFTR gene regulator
ATE451451T1 (de)	1996-07-15	2009-12-15	Us Gov Health & Human Serv	Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
AU4427897A (en)	1996-09-27	1998-04-17	American Cyanamid Company	3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
US6330090B1 (en) *	1997-02-14	2001-12-11	Photonetics	Optical fiber wavelength, multiplexer and demultiplexer
EP0975809A4 (de)	1997-03-05	2002-10-30	Univ Washington	Untersuchungverfahren zum auffinden von agentien zur selektiven inhibierung der hcv replikation
US5891705A (en)	1997-04-08	1999-04-06	Pentose Pharmaceuticals, Inc.	Method for inactivating a virus
US6884414B1 (en)	1997-04-30	2005-04-26	Mount Sinai School Of Medicine Of New York University	Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
CN1250725C (zh)	1997-05-23	2006-04-12	美国政府健康及人类服务部	从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
CA2295858C (en)	1997-07-11	2011-05-10	Yale University	Rhabdoviruses with reengineered coats
JP2001517448A (ja)	1997-09-19	2001-10-09	アメリカン・サイアナミド・カンパニー	弱毒化呼吸合胞体ウイルス
RU2236252C2 (ru) *	1998-06-12	2004-09-20	Маунт Синай Скул Оф Медсин Оф Дзе Сити Юниверсити Оф Нью-Йорк	Аттенуированные вирусы с минус-цепью с измененной антагонистической в отношении интерферона активностью для применения в качестве вакцин и фармацевтических веществ
WO1999064571A1 (en) *	1998-06-12	1999-12-16	Mount Sinai School Of Medicine Of The City University Of New York	Interferon inducing genetically engineered attenuated viruses
US6544785B1 (en)	1998-09-14	2003-04-08	Mount Sinai School Of Medicine Of New York University	Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en)	1998-09-14	2000-11-14	Mount Sinai School Of Medicine, Of The City University Of New York	Recombinant new castle disease virus RNA expression systems and vaccines
AT407958B (de)	1999-02-11	2001-07-25	Immuno Ag	Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
EP1194580B2 (de)	1999-07-14	2010-08-25	Mount Sinai School of Medicine of New York University	In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
US6800288B2 (en)	2000-03-02	2004-10-05	Polymun Scientific Immunbiologische Forschung Gmbh	Recombinant influenza A viruses
AU2001257001A1 (en)	2000-04-10	2001-10-23	Mount Sinai School Of Medicine Of New York University	Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de)	2000-04-26	2001-10-31	Conzelmann Karl Klaus	RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
AU2356002A (en)	2000-09-25	2002-04-02	Polymun Scient Immunbio Forsch	Live vaccine and method of manufacture
AUPR343601A0 (en) *	2001-02-28	2001-03-29	Dickins, Philip	Trenching machine
CA2505949A1 (en)	2002-11-13	2004-05-27	Rutgers, The State University	Process for designing inhibitors of influenza virus non-structural protein 1
CN1993140A (zh)	2004-06-01	2007-07-04	纽约大学西奈山医学院	遗传工程猪流感病毒及其应用
WO2006088481A2 (en)	2005-02-15	2006-08-24	Mount Sinai School Of Medicine Of New York University	Genetically engineered equine influenza virus and uses thereof
US20070116717A1 (en)	2005-08-01	2007-05-24	Shneider Alexander M	Influenza vaccine compositions and methods
AT502275B8 (de) *	2005-08-08	2007-08-15	Greenhills Biotechnology Res D	Immunantwort-induzierende zusammensetzungen
KR101492643B1 (ko)	2005-12-02	2015-02-12	이칸 스쿨 오브 메디슨 엣 마운트 시나이	비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
US7507411B2 (en)	2006-06-23	2009-03-24	University Of Saskatchewan	Attenuated influenza NS1 variants

1999
- 1999-06-11 RU RU2001101426/15A patent/RU2236252C2/ru active IP Right Revival
- 1999-06-11 DK DK10181977.9T patent/DK2316923T3/en active
- 1999-06-11 CA CA2334895A patent/CA2334895C/en not_active Expired - Lifetime
- 1999-06-11 DE DE69934885T patent/DE69934885T2/de not_active Expired - Lifetime
- 1999-06-11 CN CN99809582A patent/CN1312725A/zh active Pending
- 1999-06-11 DK DK10181856.5T patent/DK2316924T3/en active
- 1999-06-11 WO PCT/US1999/013144 patent/WO1999064068A1/en active Application Filing
- 1999-06-11 SK SK50021-2008A patent/SK288567B6/sk not_active IP Right Cessation
- 1999-06-11 EP EP10181856.5A patent/EP2316924B1/de not_active Expired - Lifetime
- 1999-06-11 CZ CZ2011-316A patent/CZ306637B6/cs not_active IP Right Cessation
- 1999-06-11 PL PL398576A patent/PL219128B1/pl unknown
- 1999-06-11 EP EP99927443A patent/EP1086207B1/de not_active Expired - Lifetime
- 1999-06-11 HU HU0102441A patent/HUP0102441A3/hu not_active Application Discontinuation
- 1999-06-11 JP JP2000553560A patent/JP4837827B2/ja not_active Expired - Lifetime
- 1999-06-11 ES ES99927445T patent/ES2400445T3/es not_active Expired - Lifetime
- 1999-06-11 JP JP2000553136A patent/JP4531255B2/ja not_active Expired - Lifetime
- 1999-06-11 IL IL14026499A patent/IL140264A0/xx active IP Right Grant
- 1999-06-11 MX MXPA00012403A patent/MXPA00012403A/es active IP Right Grant
- 1999-06-11 SK SK1907-2000A patent/SK288200B6/sk not_active IP Right Cessation
- 1999-06-11 MX MXPA00012402A patent/MXPA00012402A/es active IP Right Grant
- 1999-06-11 ES ES99927443T patent/ES2281177T3/es not_active Expired - Lifetime
- 1999-06-11 AU AU44343/99A patent/AU771110B2/en not_active Ceased
- 1999-06-11 IL IL14026599A patent/IL140265A0/xx active IP Right Grant
- 1999-06-11 PT PT99927445T patent/PT1085904E/pt unknown
- 1999-06-11 NZ NZ509054A patent/NZ509054A/en not_active IP Right Cessation
- 1999-06-11 CA CA2334850A patent/CA2334850C/en not_active Expired - Lifetime
- 1999-06-11 PL PL346212A patent/PL200977B1/pl not_active IP Right Cessation
- 1999-06-11 AT AT99927443T patent/ATE351901T1/de active
- 1999-06-11 EP EP99927445A patent/EP1085904B1/de not_active Expired - Lifetime
- 1999-06-11 KR KR1020007014088A patent/KR100637937B1/ko not_active Expired - Lifetime
- 1999-06-11 PL PL386473A patent/PL212316B1/pl unknown
- 1999-06-11 DK DK99927445.9T patent/DK1085904T3/da active
- 1999-06-11 ES ES10181856.5T patent/ES2650500T3/es not_active Expired - Lifetime
- 1999-06-11 DK DK99927443T patent/DK1086207T3/da active
- 1999-06-11 WO PCT/US1999/013142 patent/WO1999064570A1/en active Application Filing
- 1999-06-11 KR KR1020067011483A patent/KR20060080249A/ko not_active Ceased
- 1999-06-11 US US09/332,286 patent/US6573079B1/en not_active Expired - Lifetime
- 1999-06-11 SK SK50041-2015A patent/SK288544B6/sk not_active IP Right Cessation
- 1999-06-11 AU AU44345/99A patent/AU770619B2/en not_active Expired
- 1999-06-11 CZ CZ20004635A patent/CZ302601B6/cs not_active IP Right Cessation
- 1999-06-11 NZ NZ509055A patent/NZ509055A/xx not_active IP Right Cessation
- 1999-06-11 US US09/332,288 patent/US6669943B1/en not_active Expired - Lifetime
- 1999-06-11 EP EP10181977.9A patent/EP2316923B1/de not_active Expired - Lifetime
- 1999-06-11 ES ES10181977.9T patent/ES2653557T3/es not_active Expired - Lifetime
- 1999-06-11 BR BR9911163-2A patent/BR9911163A/pt not_active IP Right Cessation
2000
- 2000-11-28 US US09/724,419 patent/US6852522B1/en not_active Expired - Lifetime
- 2000-12-12 IL IL140264A patent/IL140264A/en not_active IP Right Cessation
- 2000-12-12 IL IL140265A patent/IL140265A/en not_active IP Right Cessation
- 2000-12-12 NO NO20006328A patent/NO20006328L/no not_active Application Discontinuation
2003
- 2003-11-14 US US10/713,732 patent/US7588768B2/en not_active Expired - Lifetime
2004
- 2004-09-20 US US10/945,718 patent/US7494808B2/en not_active Expired - Fee Related
2007
- 2007-12-24 IL IL188362A patent/IL188362A0/en not_active IP Right Cessation
2008
- 2008-02-26 IL IL189766A patent/IL189766A0/en unknown
- 2008-04-22 US US12/148,798 patent/US8057803B2/en not_active Expired - Fee Related
2009
- 2009-02-02 US US12/364,243 patent/US9352033B2/en not_active Expired - Fee Related
- 2009-02-23 US US12/391,172 patent/US20100233785A1/en not_active Abandoned
- 2009-06-08 US US12/480,410 patent/US20100158942A1/en not_active Abandoned
- 2009-12-16 JP JP2009285467A patent/JP5081220B2/ja not_active Expired - Lifetime
2010
- 2010-02-12 JP JP2010029288A patent/JP2010142248A/ja active Pending
- 2010-09-29 JP JP2010218868A patent/JP2011050384A/ja active Pending
2011
- 2011-09-30 US US13/250,846 patent/US8765139B2/en not_active Expired - Fee Related
2013
- 2013-02-15 CY CY20131100144T patent/CY1113689T1/el unknown
- 2013-06-26 JP JP2013133432A patent/JP5810134B2/ja not_active Expired - Lifetime
- 2013-08-16 JP JP2013169102A patent/JP5829655B2/ja not_active Expired - Lifetime
2014
- 2014-05-22 US US14/285,339 patent/US9387240B2/en not_active Expired - Fee Related
2016
- 2016-06-08 US US15/176,721 patent/US20160279227A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL346212A1 (en)	2002-01-28
ES2653557T3 (es)	2018-02-07
DK2316924T3 (en)	2018-01-02
US20160279227A1 (en)	2016-09-29
US8057803B2 (en)	2011-11-15
CN1312725A (zh)	2001-09-12
ES2650500T3 (es)	2018-01-18
PL200977B1 (pl)	2009-02-27
US20090053264A1 (en)	2009-02-26
EP1085904B1 (de)	2012-11-28
US20040109877A1 (en)	2004-06-10
CZ20004635A3 (en)	2001-06-13
AU771110B2 (en)	2004-03-11
EP1086207B1 (de)	2007-01-17
SK288567B6 (sk)	2018-06-01
CA2334850A1 (en)	1999-12-16
JP5810134B2 (ja)	2015-11-11
EP2316923A2 (de)	2011-05-04
EP2316924A3 (de)	2014-03-19
NZ509054A (en)	2004-01-30
HUP0102441A3 (en)	2004-10-28
JP2002517470A (ja)	2002-06-18
CA2334895A1 (en)	1999-12-16
PL212316B1 (pl)	2012-09-28
US6852522B1 (en)	2005-02-08
IL140264A (en)	2008-03-20
JP2002517229A (ja)	2002-06-18
US9387240B2 (en)	2016-07-12
SK288544B6 (sk)	2018-03-05
DK1085904T3 (da)	2013-02-25
CA2334850C (en)	2013-11-26
JP2010142248A (ja)	2010-07-01
SK19072000A3 (sk)	2001-09-11
EP1085904A4 (de)	2004-12-29
JP2011050384A (ja)	2011-03-17
US20100158942A1 (en)	2010-06-24
CZ306637B6 (cs)	2017-04-12
IL189766A0 (en)	2008-08-07
SK288200B6 (sk)	2014-06-03
US7494808B2 (en)	2009-02-24
MXPA00012402A (es)	2003-07-14
ATE351901T1 (de)	2007-02-15
JP2010099081A (ja)	2010-05-06
ES2281177T3 (es)	2007-09-16
JP2014036654A (ja)	2014-02-27
PT1085904E (pt)	2013-03-05
IL140265A (en)	2008-06-05
CZ302601B6 (cs)	2011-08-03
EP1086207A1 (de)	2001-03-28
JP5081220B2 (ja)	2012-11-28
HUP0102441A2 (hu)	2001-10-28
NZ509055A (en)	2004-02-27
WO1999064068A9 (en)	2000-03-09
CY1113689T1 (el)	2016-06-22
IL140265A0 (en)	2002-02-10
KR20010052782A (ko)	2001-06-25
US20140341948A1 (en)	2014-11-20
EP1085904A1 (de)	2001-03-28
US6669943B1 (en)	2003-12-30
PL398576A1 (pl)	2012-10-08
DK1086207T3 (da)	2007-05-29
JP4837827B2 (ja)	2011-12-14
JP5829655B2 (ja)	2015-12-09
IL188362A0 (en)	2008-03-20
EP2316924A2 (de)	2011-05-04
MXPA00012403A (es)	2003-05-15
ES2400445T3 (es)	2013-04-09
US9352033B2 (en)	2016-05-31
JP2013226154A (ja)	2013-11-07
AU4434599A (en)	1999-12-30
DK2316923T3 (en)	2018-01-08
CA2334895C (en)	2016-01-19
EP2316923A3 (de)	2014-04-09
KR100637937B1 (ko)	2006-10-23
WO1999064570A1 (en)	1999-12-16
JP4531255B2 (ja)	2010-08-25
US6573079B1 (en)	2003-06-03
US20050054074A1 (en)	2005-03-10
US20100233785A1 (en)	2010-09-16
BR9911163A (pt)	2002-01-15
EP2316924B1 (de)	2017-10-11
US8765139B2 (en)	2014-07-01
RU2236252C2 (ru)	2004-09-20
US20090203114A1 (en)	2009-08-13
DE69934885T2 (de)	2007-11-08
NO20006328L (no)	2001-02-02
WO1999064068A1 (en)	1999-12-16
AU770619B2 (en)	2004-02-26
KR20060080249A (ko)	2006-07-07
NO20006328D0 (no)	2000-12-12
WO1999064570A9 (en)	2000-03-09
US20120258134A1 (en)	2012-10-11
US7588768B2 (en)	2009-09-15
AU4434399A (en)	1999-12-30
EP2316923B1 (de)	2017-10-18
IL140264A0 (en)	2002-02-10
PL219128B1 (pl)	2015-03-31
EP1086207A4 (de)	2003-01-22

Publication	Publication Date	Title
DE69934885D1 (de)	2007-03-08	Neue methoden und interferon defiziente substrate zur vermehrung von viren
DE60035778D1 (de)	2007-09-13	Rekombinante influenzaviren zur vakzinherstellung und gentherapie
WO2006083286A3 (en)	2007-01-25	Genetically engineered swine influenza virus and uses thereof
BR9812232A (pt)	2000-07-18	Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
MX342639B (es)	2016-10-07	Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
DE60130569D1 (de)	2007-10-31	Verpackung von replikon-partikeln eines positiv-strängigen rna-virus
NO20083958L (no)	2004-02-09	Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
FR2827605B1 (fr)	2004-07-16	Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2006088481A3 (en)	2007-03-01	Genetically engineered equine influenza virus and uses thereof
WO2004085682A3 (de)	2005-03-31	Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza
ATE469170T1 (de)	2010-06-15	Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2004028478A3 (en)	2006-02-09	Functional mutations in respiratory syncytial virus
DE50110752D1 (de)	2006-09-28	Pneumovirus ns proteine antagonisieren die interferon (ifn) antwort
DE60330795D1 (de)	2010-02-11	Impfstoff gegen west nile virus
RS52448B (en)	2013-02-28	ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS

Legal Events

Date	Code	Title	Description
2008-02-07	8364	No opposition during term of opposition